Modafinil Focus

Modafinil, the active ingredient in Modafinil Focus, is a eugeroic presented as an oral tablet for oral administration. It is classified as a wakefulness‑promoting agent and is indicated for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder in adult patients.

GNH USA supplies Modafinil Focus as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide. The product complies with European Union pharmaceutical regulations and is manufactured in facilities adhering to Good Manufacturing Practice.

Modafinil is a wakefulness‑promoting agent used to manage conditions characterized by excessive daytime sleepiness, particularly when conventional treatments are insufficient.

- Narcolepsy: reduces the frequency of sudden sleep attacks and improves overall daytime alertness, enabling better participation in daily activities and enhances quality of life. - Obstructive sleep apnea (OSA): lessens residual excessive daytime sleepiness in patients already receiving optimal CPAP or other OSA therapies, supporting improved functional performance. - Shift work disorder: promotes wakefulness during scheduled work hours that fall outside the normal circadian rhythm, helping to maintain performance and safety.